MEI Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.07
- Today's High:
- $5.2
- Open Price:
- $5.15
- 52W Low:
- $4
- 52W High:
- $10.4
- Prev. Close:
- $5.06
- Volume:
- 7088
Company Statistics
- Market Cap.:
- $33.71 million
- Book Value:
- 5.156
- Revenue TTM:
- $58.77 million
- Operating Margin TTM:
- -71.26%
- Gross Profit TTM:
- $40.70 million
- Profit Margin:
- -64.44%
- Return on Assets TTM:
- -15.93%
- Return on Equity TTM:
- -74.14%
Company Profile
MEI Pharma Inc had its IPO on 2003-12-19 under the ticker symbol MEIP.
The company operates in the Healthcare sector and Biotechnology industry. MEI Pharma Inc has a staff strength of 102 employees.
Stock update
Shares of MEI Pharma Inc opened at $5.15 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.07 - $5.2, and closed at $5.07.
This is a +0.2% increase from the previous day's closing price.
A total volume of 7,088 shares were traded at the close of the day’s session.
In the last one week, shares of MEI Pharma Inc have slipped by -6.46%.
MEI Pharma Inc's Key Ratios
MEI Pharma Inc has a market cap of $33.71 million, indicating a price to book ratio of 0.8394 and a price to sales ratio of 0.7835.
In the last 12-months MEI Pharma Inc’s revenue was $58.77 million with a gross profit of $40.70 million and an EBITDA of $-41507000. The EBITDA ratio measures MEI Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, MEI Pharma Inc’s operating margin was -71.26% while its return on assets stood at -15.93% with a return of equity of -74.14%.
In Q1, MEI Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 39.2%.
MEI Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 20.6
Its diluted EPS in the last 12-months stands at $-5.79 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 20.6. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MEI Pharma Inc’s profitability.
MEI Pharma Inc stock is trading at a EV to sales ratio of 1.3924 and a EV to EBITDA ratio of 1.2747. Its price to sales ratio in the trailing 12-months stood at 0.7835.
MEI Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $134.19 million
- Total Liabilities
- $23.62 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
MEI Pharma Inc ended 2024 with $134.19 million in total assets and $0 in total liabilities. Its intangible assets were valued at $134.19 million while shareholder equity stood at $34.35 million.
MEI Pharma Inc ended 2024 with $64.55 million in deferred long-term liabilities, $23.62 million in other current liabilities, in common stock, $-395968000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.81 million and cash and short-term investments were $112.04 million. The company’s total short-term debt was $1,385,000 while long-term debt stood at $0.
MEI Pharma Inc’s total current assets stands at $120.48 million while long-term investments were $0 and short-term investments were $103.22 million. Its net receivables were $4.58 million compared to accounts payable of $4.39 million and inventory worth $0.
In 2024, MEI Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, MEI Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.07
- 52-Week High
- $10.4
- 52-Week Low
- $4
- Analyst Target Price
- $36.67
MEI Pharma Inc stock is currently trading at $5.07 per share. It touched a 52-week high of $10.4 and a 52-week low of $10.4. Analysts tracking the stock have a 12-month average target price of $36.67.
Its 50-day moving average was $6.62 and 200-day moving average was $6.09 The short ratio stood at 9.6 indicating a short percent outstanding of 0%.
Around 53.1% of the company’s stock are held by insiders while 4429.5% are held by institutions.
Frequently Asked Questions About MEI Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.